IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures
IM Therapeutics is a clinical stage company developing personalized therapies for autoimmune disease. On October 9th, they announced that...
Welcome IM Therapeutics to the C2I Family!
We would love to extend our warm welcome to IM Therapeutics! IM Therapeutics is redefining autoimmunity and transforming lives by...
C2I Accelerator has incubated over 26 portfolio companies!
At C2I Accelerator, we have successfully incubated over 26 portfolio companies including companies like SQZ Biotech, Frequency...
Create, Collaborate, and Innovate with C2I Accelerator!
At C2I Accelerator, we aim to create new ideas to target challenges in biotechnology and pharmaceuticals. We form a collaborative...
C2I features 20,000 sq.ft. of fully equipped lab and office space...
C2I offers a newly renovated 20,000 sq. ft. facility, fully equipped with chemistry, biology, and tissue culture labs with high-end...
SynerK shares their experience with C2I Accelerator...
If you have an innovative idea, C2I Accelerator is the life science incubator that can make your ideas a reality! SynerK, an alumni of...
Frequency Therapeutics Closes $62MM Series C Financing
Congratulations to Frequency Therapeutics! They have announced the close of their $62mm Series C financing to expand research of their...
Welcome to C2I's newest tenants: SynerK, Inc.
We would like to extend a warm welcome to the newest members of the C2I family. SynerK, Inc. is a biotechnology company engaged in the...
